# Bioavailability of EPA + DHA in a SMEDS Formulation

> **NCT03443076** · NA · COMPLETED · sponsor: **Midwest Center for Metabolic and Cardiovascular Research** · enrollment: 24 (actual)

## Conditions studied

- Bioavailability

## Interventions

- **DIETARY_SUPPLEMENT:** EPA + DHA in SMEDS Formulation
- **OTHER:** Lovaza (active comparator; already FDA approved)

## Key facts

- **NCT ID:** NCT03443076
- **Lead sponsor:** Midwest Center for Metabolic and Cardiovascular Research
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-16
- **Primary completion:** 2018-04-05
- **Final completion:** 2018-04-15
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03443076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03443076, "Bioavailability of EPA + DHA in a SMEDS Formulation". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03443076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*